Vasculo-Protective Cover: A Novel Action of Metformin

Authors

  • Rabia Arshad
  • Nasim Karim

Keywords:

Type 2 diabetes, Oral anti-diabetic drugs, Metformin ,Vasculo-protective effects, Endothelial dysfunctions

Abstract

Type 2 diabetes is associated with multiple changes/complications in the body that affects almost every organ and system. In
the cardiovascular system main pathology lies in the vascular endothelium leading to atherosclerosis and arteriosclerosis.
Different treatment options are available for diabetes including both oral and injectable drugs. Oral drugs have better compliance
like Sulfonylureas, Alpha glucosidase inhibitors, Glitazones and Maglitinides. These groups of anti-hyperglycemic drugs
maintain blood glucose level, providing diabetics cost effective better life through a physiological route. However, it has been
documented that these drugs do not delay vascular complications in diabetic patients. Metformin is the first line oral anti-diabetic
drug from biguanide group used to treat type 2 diabetes mellitus. It is a euglycemic agent which decreases glucose levels and
have additional benefit of decreasing the progression of vascular effects in multiple ways.

References

American Diabetic Association. Diagnosis and classification

of diabetes mellitus. Diabetes care 2004; 27(1):5-10

George B, Cebioglu M, Yeghiazaxyn K. Inadequate diabetic

care: global figures cry for preventive measures

and personalized treatment. EPMA journal 2010; 1:13-8

Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational

diabetes mellitus and its association with Type

diabetes. Diabetic Medicine 2003; 21:103-13

Catalano PM, Tyzbir ED, Wolfe RR, Calles J, Roman

NM, Amini SB et al. Carbohydrate metabolism during

pregnancy in control subjects and women with gestational

diabetes. Am J Physiol 1993; 264: 60–7

Grant P. Beneficial effects of metformin on homeostasis

and vascular function in man. Diabetes Metabolism 200-

; 29( 2) : 6S44-52

Tripathi KD. Insulin, Oral hypoglycemic drugs and glucagon

In: Essentials of Medical Pharmocology; Tripathi

M editor. Chapter 19, sixth edition. Jaypee brothers India

p 255-8

Agular L G, Bahla L , Villela N ,Laflor C ,Sicuro F, Wiernsperger

N et al. Metformin improves endothelial vascular

reactivity in first degree relatives of type 2 diabetic

patients with metabolic syndrome and normal glucose

tolerance . Diabetes Care 2006 ;29(5) :1083-9

Vapaatalo H, Mervaala E. Clinically important factors

influencing endothelial functions .Med Sci Monit 2001

;7(5) :1075-85

Schachinger V, Britten M, Zeiher A M. Prognostic effects

of impact of coronary vasodilators dysfunction on adverse

long term outcome of coronary heart disease. Circulation

;101: 1899-906

Hsuch W A, Quinones M J. Role of endothelial dysfunction

in insulin resistance. Am j Cardiol 2003 ; 92: 10-17

Davignor J, Peter G. Role of endothelial dysfunction in

atherosclerosis. Circulation 2004;109: 27-32 (doi: 10.11

/01.CIR.000131515.03336.f8)

Casey R C, Joyce M, Moore K, Thompson C, Fitzgerald

P, Bouchier-D J. Two weeks treatment with parvostatin

improves ventriculo-vascular dynamics interactions in

young men with type 1 diabetes. Diabetes and vascular

disease research 2007; 4(1):53-61

Natali A ,Baldeweg S, Toschi E, Capaldo B, Barbaro D,

Gastaldelli A et al. Vascular effects of improving metabolic

control with metformin or rosiglitazone in type 2

diabetes. Diabetes care 2004;27(6): 1349-57

Straughan J L .Focus on metformin – a major cardiovascular

medication .Cardiovascular Journal of Africa 2007

;18(5):331-3

Strack T. Metformin: a review. Drugs Today 2008; 44(4):

-14

Nathan DM, Buse J B , Davidson M B, Heine RJ , Holman

R, Sherwin R. Management of hyperglycemia in

type 2 diabetes :a consensus algorithm for the initiation

and adjustment of therapy. Diabetologia 2006;49:1711-21

Ross SA, Marine Elioe J. Incretin agents in Type 2 diabetes.

Canadian family physician 2010; 56(7): 639-48

Rajos LBA, Rajos MB. Metformin: an old but still the

best treatment for treatment for type 2 diabetes. Diabetology

& Metabolism Syndrome 2013; 5:6- 9 (doi: 10.11

/1758-5996-5-6)

Correia S, Carvalho C , Santos MS, Seica R, Oliveira

CR , Moreira P I. Mechanisms of action of metformin

in type 2 diabetes and associated complications: an over

view. Mini Rev Med Chem 2008; 8(13): 1343-54

Ascis-Buturovic B, Kacila M. Effects of basal insulin

analog and metformin on glycemia control and weight

as risk factors for endothelial dysfunction. Bosn J Med

Sci 2008; 8(4): 309-12

Home PD. Impact of the UKPDS. An overview. Diabet

Med 2008;25(2):2-8

Papanas N, Maltezos E, Mikhailidis DP. Metformin:

diamonds forever. Expert Opin Pharmacother 2009; 10

(15): 2395-7

Wiernsperger NF, Bouskela E. Microcirculation in insulin

resistance and diabetes: more then just a complication.

Diabetes and Metabolism 2003; 29 (4): 6577-87

Majithiya JB, Balaraman R. Metformin reduces blood

pressure and restores endothelial function in aorta of

streptozotocin- induced diabetic rats. Life Sci 2006; 78

(22): 2615-24

Xie W, Zhang SD, Ou XP, Yang TL. Protective effects

of metformin on low density lipoprotein –induced endothelial

dysfunction in rats. Nang Fang Yi Ke Da Xue

Xue Bao 2009; 29(5):890-3

Mather KJ, Verma S, Anderson TJ. Improved endothelial

functions with metformin in type 2 diabetes mellitus. J

Am Coll Cardiol 2001;37:1344-50

Jager DJ, Kooy A, Lehert PH, Bets D, Wulffele MG,

Teerlink T et al. Effects of short term treatment on markers

of endothelial function and inflammatory activity

in type 2 diabetes mellitus: a randomized, placebo- controlled

trial. Journal of internal medicine 2005 ; 257:100-

(doi: 10.1111/j.1365-2796.2004.01420.x)

Alvim de Lima LM, Wiernsperger N, Kraemer-Aguiar

LG, Bouskela E. Short –term treatment with metformin

improves the cardiovascular risk profile in first –degree

relatives of subjects with type 2 diabetes mellitus who

have a metabolic syndrome and normal glucose tolerance

without change in C - reactive protein or fibrinogen. Clinics

; 64(5): 415-30

Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker

A J M et al .Long term effects of metformin on

metabolism and macrovascular disease in patients with

type 2 diabetes mellitus. Arch Intern Med 2009; 169(6)

:616-25

Scapello J H, Howlett HC. Metformin therapy and clinical

uses. Diab Vasc Dis Res 2008.; 5(3): 157-67

Baily CJ. Metformin: Effects on micro and macrovascular

complication in type 2 diabetes. Cardiovasc Drugs Ther

;22: 215-24

Anfossi G, Russo I, Bonomo K, Trovati M. The cardiovascular

effects of metformin: further reasons to consider

in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol

; 8(3): 327-37

Vascular–protective effects of metformin. SA Journal

of diabetes and vascular disease 2007 ;4(4): 198-201

Kirpichnikov D, Macfarlane S I, Sower J R. Metformin:

An Update. Ann Intern Med 2002; 137:25-33

Papanas N, Maltezos E .Oral antidiabetic agents: antiatherosclerotic

properties beyond glucose lowering?

Curr Pharm Des 2009;15(27):3179-92

Orio F, Palomba S, Cascella T, De Simon B, Manguso

F, Savastano S et al. Improvement in endothelial structure

and function in young normal –weight women with polycystic

syndrome: Result of a 6- month study. The Journal

of Clinical Endocrinology 2005;90(11):6072-6

Palomba S, Falbao A, Giallauria F, Russo T, Tolino A,

Zullo F et al. Effects of metformin with and without supplementation

with folate on homocysteine levels and

vascular endothelium of women with polycystic ovary

syndrome. Diabetes care 2010 ;33(2): 246-51

Mather K J, Verma S, Anderson TJ. Improved endothelial

functions with metformin in type 2 diabetes mellitus.J

Am Coll Cardiol 2001; 37: 1344-50

Wiernsperger N F. Review: 50 years later: metformin a

vascular drug with anti diabetic properties? The British

Journal of Diabetes and Vascular Diseases 2007; 7(5):

-10

English PJ, Ashcroft A, Patterson M. Metformin prolongs

the postprandial fall in plasma ghrelin concentration in

type 2 diabetes. Diabetes Metab Res Rev 2007; 23: 299-303

Downloads

Published

2015-09-03

How to Cite

Arshad, R. ., & Karim, N. . (2015). Vasculo-Protective Cover: A Novel Action of Metformin. Journal of Bahria University Medical and Dental College, 5(3), 105–108. Retrieved from https://jbumdc.bahria.edu.pk/index.php/ojs/article/view/122

Issue

Section

Review Article

Most read articles by the same author(s)

1 2 3 > >>